Q 203

Drug Profile

Q 203

Alternative Names: Q203

Latest Information Update: 19 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Qurient Co
  • Class Amides; Antibacterials; Antituberculars; Imidazoles; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Bacterial growth modulators; Electron transport complex III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 01 Jul 2016 Qurient completes a phase I trial in Tuberculosis (In volunteers) in USA (NCT02530710)
  • 01 Aug 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO)
  • 13 Feb 2014 Q 203 licensed to Infectex in Russia and Commonwealth of Independent States
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top